Bolt Biotherapeutics (BOLT) to Release Quarterly Earnings on Wednesday

Bolt Biotherapeutics (NASDAQ:BOLT) will likely be releasing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Bolt Biotherapeutics to post earnings of ($4.27) per share and revenue of $0.6670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Thursday, March 12th. The company reported ($3.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.27) by $0.43. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $0.67 million. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%. On average, analysts expect Bolt Biotherapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $4.29 on Wednesday. The company’s 50-day moving average is $5.21 and its two-hundred day moving average is $5.33. Bolt Biotherapeutics has a 1-year low of $3.91 and a 1-year high of $9.66. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.59 and a quick ratio of 3.59. The firm has a market capitalization of $8.24 million, a price-to-earnings ratio of -0.24 and a beta of 0.94.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its position in shares of Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after acquiring an additional 26,400 shares during the period. Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth $89,000. Shay Capital LLC purchased a new stake in Bolt Biotherapeutics during the 3rd quarter worth about $85,000. Finally, Squarepoint Ops LLC raised its position in Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares in the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Friday, March 13th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus price target of $34.00.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.